Trial of Rapid-acting Intranasal Esketamine for Treatment-resistant Major Depressive Disorder (TRANSFORM-2)
Brief description of study
We are currently enrolling participants for a clinical research study to look at the effectiveness and safety of an investigational medication (given as a nasal spray) in patients with depression who have not responded to prior treatment with at least two antidepressants.
If you are eligible for this study and choose to participate, you will
receive all study visits and study-related medical care at no cost to you.
Compensation for your time and travel may also be provided.
Detailed description of study
There are three phases in the study:
• A screening phase of up to 7 weeks
• A 4-week treatment phase
• A 24-week follow-up phase
o Some patients will be given the option to continue
treatment in another study and will not have a
follow-up phase.
Patients who do not have a follow-up phase will be in the
study for 11 weeks; all other patients will be in the study for
35 weeks
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Depression, Major depression, Depression, depression
-
Age: Between 18 Years - 64 Years
-
Gender: All
Updated on
28 Jul 2017.
Study ID: TX1047
